Download PDF
Aktuelle Kardiologie 2013; 2(3): 177-182
DOI: 10.1055/s-0032-1328488
Übersichtsarbeit
Georg Thieme Verlag KG Stuttgart · New York

Interventionelle Therapie der arteriellen Hypertonie

Interventional Therapy of Arterial Hypertension
B. Blüm
II. Medizinische Klinik, Klinikum Coburg
› Author Affiliations
Further Information

Publication History

Publication Date:
11 June 2013 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die arterielle Hypertonie ist mit eine der häufigsten chronischen Erkrankungen und ein großer Risikofaktor für die Entstehung von kardiovaskulären Erkrankungen. Der therapieresistente Hypertonus ist definiert durch einen systolischen Praxisblutdruck ≥ 160 mmHg bzw. ≥ 150 mmHg bei Patienten mit Diabetes Typ 2, unter 3-fach antihypertensiver Therapie inklusive einem Diuretikum. Eine optimale antihypertensive Therapie ist bei jedem Patienten mit resistenter Hypertonie obligat. Vor der Behandlung gilt es, eine sekundäre Hypertonieform sowie eine Pseudoresistenz auszuschließen. Die neuen interventionellen Methoden zur Behandlung der therapieresistenten Hypertonie zeigen bisher erfolgreiche Kurzeitdaten. Die Langzeitdaten stehen noch aus. Aktuell gibt es zahlreiche neue Entwicklungen in diesem Bereich. Welche sich davon etablieren und behaupten können, wird die Zukunft zeigen.

Abstract

Resistant hypertension is a common clinical problem. The exact prevalence of resistant hypertension is unknown. The incidence of resistant hypertension will likely increase as the population becomes more elderly and heavier. The definition for resistant hypertension is a systolic office blood pressure ≥ 160 mmHg or ≥ 150 mmHg by patients with diabetes type 2, undergoing a tripple antiypertensive medication including diureticum. An optimal antihypertensive drug treatment is required. The aim of therapy is prevention of end-organ damage and reduction of cardiovascular mortality. The new interventional approach to this old problem seems to be effective. Long follow-up studies will show which method is the best.

Schlüsselwörter

renale sympathische Denervation - Symplicity-resistente Hypertonie - EnligHTN I - Baroreflexstimulation

Key words

renal sympathetic denervation - symplicity-resistant hypertension - EnligHTN I - baroreflex stimulation
 

  • Literatur

  • 1 Calhoun DA, Jones D, Textor S et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117: e510-e526
    CrossrefPubMedGoogle Scholar
  • 2 Lowel H, Meisinger C, Heier M et al. [Epidemiology of hypertension in Germany. Selected results of population-representative cross-sectional studies]. Dtsch Med Wochenschr 2006; 131: 2586-2591
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Mann SJ. Drug therapy for resistant hypertension: Simplifying the approach. J Clin Hypertens (Greenwich) 2011; 13: 120-130
    CrossrefPubMedGoogle Scholar
  • 4 Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL et al. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 2007; 131: 453-459
    CrossrefPubMedGoogle Scholar
  • 5 Goncalves SC, Martinez D, Gus M et al. Obstructive sleep apnea and resistant hypertension: a case-control study. Chest 2007; 132: 1858-1862
    CrossrefPubMedGoogle Scholar
  • 6 Douma S, Petidis K, Doumas M et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008; 371: 1921-1926
    Google Scholar
  • 7 Krum H, Sobotka P, Mahfoud F et al. Device-based antihypertensive therapy: therapeutic modulation of the autonomic nervous system. Circulation 2011; 123: 209-215
    CrossrefPubMedGoogle Scholar
  • 8 Scheffers IJ, Kroon AA, Schmidli J et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol 2010; 56: 1254-1258
    CrossrefPubMedGoogle Scholar
  • 9 Krum H et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275-1281
    CrossrefPubMedGoogle Scholar
  • 10 Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011; 57: 911-917
    CrossrefPubMedGoogle Scholar
  • 11 Esler MD, Krum H, Sobotka PA et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903-1909
    CrossrefPubMedGoogle Scholar
  • 12 Mahfoud F, Vonend O, Bruck H et al. [Expert consensus statement on interventional renal sympathetic denervation for hypertension treatment]. Dtsch Med Wochenschr 2011; 136: 2418
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Mahfoud F, Cremers B, Janker J et al. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension 2012; 60: 419-424
    CrossrefPubMedGoogle Scholar
  • 14 Kandzari DE, Bhatt DL, Sobotka PA et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol 2012; 35: 528-535
    CrossrefPubMedGoogle Scholar
  • 15 Witkowski A, Prejbisz A, Florczak E et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 2011; 58: 559-565
    CrossrefPubMedGoogle Scholar
  • 16 Brandt MC, Mahfoud F, Reda S et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 2012; 59: 901-909
    CrossrefPubMedGoogle Scholar